

FIGURE 1




FIGURE 2a

3/19




FIGURE 2b




FIGURE 3

HPLC of isoliquirtigenin




FIGURE 4

6/19

UV spectrum of Isoliquiritigenin




FIGURE 5

I-3-4





FIGURE 6a

8/19



1-3-4 C13-2 d1=4s scan 10000

Pulse Sequence: e2p01

FIGURE 6b

9/19




FIGURE 7

Cell viability (MTT) curves for Wogonin treatment of LNCaP and DU145




FIGURE 8

Cell viability (MTT) curves for isoliquiritigenin treatment of LNCaP, DU145 and MCF-7




FIGURE 9





FIGURE 10

Effects of Isoliquiritigenin and Wogonin on cell cycle of LNCaP




FIGURE 11

Effects of Isoliquiritigenin and Wogonin on cell cycle of DU145




FIGURE 12

ERE-Luc Reporter Activation in 293 Cells
Transfected with hERalpha




FIGURE 13

ERE-Luc Reporter Activation in 293 Cells
Transfected with hERbeta




FIGURE 14


Inhibitory activity of isoliquiritigenin on COX-2

Figure 15




Figure 16




Figure 17